Is dose-dependent response to bacillus Calmette-Guérin treatment in urothelial carcinoma?

Fabricio Racca, Rafael Morales-Barrera, Joan Carles

Research output: Contribution to journalArticleResearchpeer-review

Abstract

© Translational Cancer Research. All rights reserved. Bacillus Calmette-Guérin (BCG) intravesical instillation therapy has been established as a standard of care treatment for high-risk non-muscle invasive urothelial carcinoma (NMIUC). To date, many clinical have demonstrated a direct antitumor activity, prevention of tumor recurrence, reductions in tumor progression and, consequently, tumor specific mortality and improvement in overall survival. Nevertheless, the local adverse events arising from BCG intravesical account for about one-third of treatment discontinuations. Strategies to minimize the side effects are needed.
Original languageEnglish
Pages (from-to)S179-S181
JournalTranslational Cancer Research
Volume6
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Bacillus Calmette-Guérin (BCG)
  • High doses
  • Non-muscle invasive (NMI)
  • Standard doses (SD)
  • Toxicity
  • Urothelial carcinoma (UC)

Fingerprint

Dive into the research topics of 'Is dose-dependent response to bacillus Calmette-Guérin treatment in urothelial carcinoma?'. Together they form a unique fingerprint.

Cite this